Literature DB >> 29948556

Potential of Fecal Calprotectin as an Objective Marker to Discriminate Hospitalized Patients with Acute Severe Colitis from Outpatients with Less Severe Disease.

Saurabh Kedia1, Saransh Jain1, Sandeep Goyal1, Sawan Bopanna1, Dawesh P Yadav1, Vikas Sachdev1, Peush Sahni2, Sujoy Pal2, Nihar Ranjan Dash2, Govind Makharia1, Simon P L Travis3, Vineet Ahuja4.   

Abstract

BACKGROUND: Acute severe colitis (ASC) is conventionally diagnosed by Truelove and Witts' criteria which are non-specific and can be affected by other pathologic conditions. Fecal calprotectin (FCP) is a gut-specific marker of inflammation which can predict short-term outcomes in patients with ASC. We aimed to define the role of FCP in the diagnosis of ASC.
METHODS: This prospective observational cohort study included adult patients (> 18 years) with ulcerative colitis (UC) for whom FCP was measured and was under follow-up from April 2015 to December 2016. Patients were divided into two cohorts: (1) all consecutive hospitalized patients with ASC as defined by Truelove and Witts' criteria; (2) outpatients with active UC (defined by Mayo score) who did not fulfill Truelove and Witts' criteria. FCP levels were compared between the two cohorts, and a cutoff for FCP to diagnose ASC was determined.
RESULTS: Of 97 patients, 49 were diagnosed with ASC (mean age: 36.1 ± 11.9 years, 36 males) and 48 with active UC (mean age: 37.9 ± 12.4 years, 25 males). Median FCP levels were significantly higher in patients with ASC [1776(952-3123) vs 282(43-568) µg/g, p < 0.001] than mild to moderately active UC (n = 48) or moderately active UC [n = 35, 1776(952-3123) vs 332(106-700) µg/g, p < 0.001]. A FCP cutoff of 782 μg/g of stool had excellent diagnostic accuracy, with an area under the curve of 0.92(95% CI 0.87-0.97), sensitivity of 84% and specificity of 88% to differentiate ASC from active UC.
CONCLUSION: FCP could differentiate ASC from mild to moderate patients with UC, but requires validation before clinical use.

Entities:  

Keywords:  Acute severe colitis; Fecal calprotectin; Hospitalization; Mayo score; Ulcerative colitis

Mesh:

Substances:

Year:  2018        PMID: 29948556     DOI: 10.1007/s10620-018-5157-6

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  15 in total

1.  Calprotectin, a faecal marker of organic gastrointestinal abnormality.

Authors:  M K Fagerhol
Journal:  Lancet       Date:  2000-11-25       Impact factor: 79.321

2.  THE COURSE AND PROGNOSIS OF ULCERATIVE COLITIS.

Authors:  F C EDWARDS; S C TRUELOVE
Journal:  Gut       Date:  1963-12       Impact factor: 23.059

3.  Cortisone in ulcerative colitis; preliminary report on a therapeutic trial.

Authors:  S C TRUELOVE; L J WITTS
Journal:  Br Med J       Date:  1954-08-14

4.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.

Authors:  Mark S Silverberg; Jack Satsangi; Tariq Ahmad; Ian D R Arnott; Charles N Bernstein; Steven R Brant; Renzo Caprilli; Jean-Frédéric Colombel; Christoph Gasche; Karel Geboes; Derek P Jewell; Amir Karban; Edward V Loftus; A Salvador Peña; Robert H Riddell; David B Sachar; Stefan Schreiber; A Hillary Steinhart; Stephan R Targan; Severine Vermeire; B F Warren
Journal:  Can J Gastroenterol       Date:  2005-09       Impact factor: 3.522

5.  Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse.

Authors:  Javier P Gisbert; Fernando Bermejo; Jose-Lázaro Pérez-Calle; Carlos Taxonera; Isabel Vera; Adrian G McNicholl; Alicia Algaba; Pilar López; Natalia López-Palacios; Marta Calvo; Yago González-Lama; Jose-Antonio Carneros; Marta Velasco; José Maté
Journal:  Inflamm Bowel Dis       Date:  2009-08       Impact factor: 5.325

6.  Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?

Authors:  Valle García-Sánchez; Eva Iglesias-Flores; Raúl González; Javier P Gisbert; José María Gallardo-Valverde; Angel González-Galilea; Antonio Naranjo-Rodríguez; Juan F de Dios-Vega; Jordi Muntané; Federico Gómez-Camacho
Journal:  J Crohns Colitis       Date:  2009-12-02       Impact factor: 9.071

7.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.

Authors:  K W Schroeder; W J Tremaine; D M Ilstrup
Journal:  N Engl J Med       Date:  1987-12-24       Impact factor: 91.245

Review 8.  A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS.

Authors:  Stacy B Menees; Corey Powell; Jacob Kurlander; Akash Goel; William D Chey
Journal:  Am J Gastroenterol       Date:  2015-03-03       Impact factor: 10.864

9.  Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes.

Authors:  Alain M Schoepfer; Christoph Beglinger; Alex Straumann; Ekaterina Safroneeva; Yvonne Romero; David Armstrong; Carsten Schmidt; Michael Trummler; Valérie Pittet; Stephan R Vavricka
Journal:  Inflamm Bowel Dis       Date:  2013-02       Impact factor: 5.325

10.  Accuracies of fecal calprotectin, lactoferrin, M2-pyruvate kinase, neopterin and zonulin to predict the response to infliximab in ulcerative colitis.

Authors:  Anne-Claire Frin; Jérôme Filippi; Gilles Boschetti; Bernard Flourie; Jocelyne Drai; Patricia Ferrari; Xavier Hebuterne; Stéphane Nancey
Journal:  Dig Liver Dis       Date:  2016-09-13       Impact factor: 4.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.